A federal judicial panel ordered that lawsuits alleging vision loss from Novo Nordisk’s (NVO) and Eli Lilly’s (LLY) weight-loss drugs be centralized before a judge in Philadelphia, Reuters’ Diana Novak Jones reports. The panel ruled the cases should form a separate multidistrict litigation rather than be added to existing litigation over gastrointestinal side effects.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Wegovy Study in Korea: A Potential Game-Changer for Obesity Treatment
- Novo Nordisk’s New Study on Ziltivekimab: A Potential Game-Changer in Heart Attack Treatment
- Novo Nordisk’s New Study on GLP-1 Medications: What Investors Need to Know
- Novo Nordisk’s CagriSema Study: A Potential Game-Changer in Diabetes Management
- Novo Nordisk’s CagriSema Study: A Potential Breakthrough for Chronic Kidney Disease and Diabetes